REFERENCES
- Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19(2):149–154.
- Parving HH. Microalbuminuria in essential hypertension and diabetes mellitus. J Hypertens Suppl. 1996;14(2):S89–S93.
- Bahrami H, Bluemke DA, Kronmal R, . Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol. 2008;51(18):1775–1783.
- Assadi F. Relation of left ventricular hypertrophy to microalbuminuria and C-reactive protein in children and adolescents with essential hypertension. Pediatr Cardiol. 2008;29(3):580–584.
- Marcovecchio ML, Giannini C, Widmer B, . C-reactive protein in relation to the development of microalbuminuria in type 1 diabetes: the Oxford regional prospective study. Diabetes Care. 2008;31(5):974–976.
- Moubarak M, Jabbour H, Smayra V, . Cardiorenal syndrome in hypertensive rats: microalbuminuria, inflammation and ventricular hypertrophy. Physiol Res. 2012;61(1):13–24.
- Wang TJ, Evans JC, Meigs JB, . Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation. 2005;111(11):1370–1376.
- Mancia G, De BG, Dominiczak A, . 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–1187.
- Fukumoto S, Ishimura E, Motoyama K, . Antialbuminuric advantage of cilnidipine compared with L-type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuria. Diabetes Res Clin Pract. 2012;97(1):91–98.
- Nakagawa N, Fujino T, Kabara M, . Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate. Hypertens Res. 2011;34(10):1121–1126.
- Jalal S, Sofi FA, Abass SM, . Effect of amlodipine and lisinopril on microalbuminuria in patients with essential hypertension: a prospective study. Indian J Nephrol. 2010;20(1):15–20.
- Mancia G, Giannattasio C, Seravalle G, Quarti-Trevano F, Grassi G. Protective effects of renin-angiotensin blockade beyond blood pressure control. J Hum Hypertens. 2009;23(9):570–577.
- Yusuf S, Teo KK, Pogue J, . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559.
- Rodriguez-Perez JC, Garcia-Bello MA, Anabitarte-Prieto A, . Anti-albuminuric effects of the angiotensin AT1 receptor blocker telmisartan in hypertensive patients. Clin Exp Hypertens. 2011;33(8):506–510.
- Griffin KA, Bidani AK. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol. 2006;1(5):1054–1065.
- Fukutomi M, Hoshide S, Eguchi K, Watanabe T, Shimada K, Kario K. Differential effects of strict blood pressure lowering by losartan/hydrochlorothiazide combination therapy and high-dose amlodipine monotherapy on microalbuminuria: the ALPHABET study. J Am Soc Hypertens. 2012;6(1):73–82.
- Webster J, Robb OJ, Jeffers TA, Scott AK, Petrie JC, Towler HM. Once daily amlodipine in the treatment of mild to moderate hypertension. Br J Clin Pharmacol. 1987;24(6):713–719.
- Toma L, Stancu CS, Sanda GM, Sima AV. Anti-oxidant and anti-inflammatory mechanisms of amlodipine action to improve endothelial cell dysfunction induced by irreversibly glycated LDL. Biochem Biophys Res Commun. 2011;411(1):202–207.